New combo drug trial aims to fight resistant lung cancer

NCT ID NCT07315113

Recruiting now Disease control Sponsor: Nuvectis Pharma, Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing whether adding an experimental drug called NXP900 to an existing lung cancer medication (osimertinib) can help control advanced lung cancer that has started to grow again. It is for adults with a specific genetic change (EGFR mutation) whose cancer progressed while on osimertinib. The main goals are to check the safety of the combination and see if it can shrink tumors or stop them from growing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR MUTATION POSITIVE NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Massachusetts General Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02114, United States
NEXT Houston
RECRUITING

Houston, Texas, 77054, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.

EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS EGFR MUTATION POSITIVE NON-SMALL CELL LUNG CANCER